GLAND PHARMA
|
GLAND PHARMA Last 5 Year Cashflow Statement History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|
Profit Before Tax | ₹1,055 Cr | ₹1,619 Cr | ₹1,335 Cr | ₹993 Cr |
Adjustment | ₹38 Cr | ₹-28 Cr | ₹17 Cr | ₹32 Cr |
Changes In working Capital | ₹-418 Cr | ₹-393 Cr | ₹-436 Cr | ₹-80 Cr |
Cash Flow after changes in Working Capital | ₹675 Cr | ₹1,197 Cr | ₹916 Cr | ₹945 Cr |
Cash Flow from Operating Activities | ₹364 Cr | ₹791 Cr | ₹605 Cr | ₹701 Cr |
Cash Flow from Investing Activities | ₹1,208 Cr | ₹-1,003 Cr | ₹-1,524 Cr | ₹-766 Cr |
Cash Flow from Financing Activities | ₹15 Cr | ₹35 Cr | ₹1,238 Cr | ₹-6.87 Cr |
Net Cash Inflow / Outflow | ₹1,587 Cr | ₹-177 Cr | ₹319 Cr | ₹-72 Cr |
Opening Cash & Cash Equivalents | ₹319 Cr | ₹492 Cr | ₹169 Cr | ₹236 Cr |
Cash & Cash Equivalent on Amalgamation / Take over / Merger | - | - | - | - |
Cash & Cash Equivalent of Subsidiaries under liquidations | - | - | - | - |
Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - | - |
Effect of Foreign Exchange Fluctuations | ₹3.00 Cr | ₹3.31 Cr | ₹3.58 Cr | ₹5.11 Cr |
Closing Cash & Cash Equivalent | ₹1,909 Cr | ₹319 Cr | ₹492 Cr | ₹169 Cr |
Compare Cashflow Statement of peers of GLAND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLAND PHARMA | ₹28,477.5 Cr | -2.7% | -3.7% | 32.7% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹360,920.0 Cr | -2.3% | -6.5% | 55.3% | Stock Analytics | |
CIPLA | ₹113,794.0 Cr | 4.1% | -4.8% | 55.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹106,860.0 Cr | 7.8% | 17.4% | 20.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹104,316.0 Cr | 4% | 0.8% | 29.4% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,380.9 Cr | -1.2% | -5.2% | 83.9% | Stock Analytics |
GLAND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLAND PHARMA | -2.7% |
-3.7% |
32.7% |
SENSEX | 0.9% |
1.5% |
23.6% |
You may also like the below Video Courses